Follow
Hisaaki Kawabata
Hisaaki Kawabata
Medical Student, University of Rochester School of Medicine and Dentistry
Verified email at urmc.rochester.edu
Title
Cited by
Cited by
Year
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
JM Carreño, H Alshammary, J Tcheou, G Singh, AJ Raskin, H Kawabata, ...
Nature 602 (7898), 682-688, 2022
4962022
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study
A Ozonoff, J Schaenman, ND Jayavelu, CE Milliren, CS Calfee, CB Cairns, ...
EBioMedicine 83, 2022
462022
Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B. 1.617. 2, B. 1.351, B. 1.1. 7+ E484K and a sub-variant of C. 37
JM Carreño, H Alshammary, G Singh, A Raskin, F Amanat, A Amoako, ...
medRxiv, 2021.07. 21.21260961, 2021
242021
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
S Ponce-de-León, M Torres, LE Soto-Ramírez, JJ Calva, ...
npj Vaccines 8 (1), 67, 2023
232023
Safety and immunogenicity analysis of a Newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in sprague dawley rats
J Tcheou, A Raskin, G Singh, H Kawabata, D Bielak, W Sun, ...
Frontiers in Immunology 12, 791764, 2021
232021
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results …
S Ponce-de-León, M Torres, LE Soto-Ramírez, JJ Calva, ...
medRxiv, 2022
192022
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
JM Carreño, A Raskin, G Singh, J Tcheou, H Kawabata, C Gleason, ...
Science Translational Medicine 15 (683), eabo2847, 2023
122023
An In Vitro Microneutralization Assay for Influenza Virus Serology
F Cuevas, H Kawabata, F Krammer, JM Carreño
Current Protocols 2 (7), e465, 2022
122022
SARS-CoV-2 spike-binding antibody longevity and protection from reinfection with antigenically similar SARS-CoV-2 variants
J Kubale, C Gleason, JM Carreño, K Srivastava, G Singh, A Gordon, ...
MBio, 2022
112022
Group PPS; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
JM Carreno, H Alshammary, J Tcheou, G Singh, A Raskin, H Kawabata, ...
Nature, 2021
52021
The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines
JM Carreño, A Raskin, G Singh, J Tcheou, H Kawabata, C Gleason, ...
medRxiv, 2022.01. 25.22269808, 2022
12022
Correction: An In Vitro Microneutralization Assay for Influenza Virus Serology
F Cuevas, H Kawabata, F Krammer, JM Carreño
Current Protocols 2 (9), e567, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–12